Pembrolizumab in metastatic NSCLC: Now added benefit for subpopulations
In early July, the German Institute for Quality and Efficiency in Health Care (IQWiG) conducted two early benefit assessments to investigate whether certain drug combinations with pembrolizumab have advantages in comparison ...
Sep 20, 2019
0
0